文献速递妇科

阿沙利莫基菲洛利斯巴(ADXS-HPV)治疗铂类难治性宫颈癌的II期研究:NRG肿瘤学/妇科肿瘤学组研究

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
PubMed 文献 · Gynecol Oncol · 2020-07-06

这项II期两阶段试验评估了治疗性疫苗ADXS-HPV在至少一线治疗后进展的晚期宫颈癌患者中的安全性和12个月总生存率。50例可评估患者中12个月OS为38%(n=19),中位OS 6.1个月,中位PFS 2.8个月,最常见治疗相关不良事件为疲乏、寒战、发热、恶心和贫血,多数为1-2级。结论认为在该剂量和方案下ADXS-HPV可耐受,并达到方案规定的活性基准,值得进一步研究。

要点

  • 50例可评估患者中12个月OS为38%(n=19),达到方案规定的35%活性基准。
  • 中位OS为6.1个月(95%CI:4.3-12.1),中位PFS为2.8个月(95%CI:2.6-3.0)。
  • 最常见治疗相关不良事件为疲乏、寒战、发热、恶心和贫血,多数为1-2级。

核心结论

  • 在研究的剂量和方案下,ADXS-HPV免疫治疗可耐受,并达到方案规定的活性基准,值得在宫颈癌患者中进一步研究。

研究设计与样本

  • 两阶段II期试验(GOG protocol 265/NCT01266460),纳入≥18岁、晚期宫颈癌、GOG体力状态评分为0或1的志愿者。
  • 第一阶段最多接受三剂ADXS-HPV(1×10^9集落形成单位,250mL静脉输注15分钟,每28天一次),第二阶段治疗至进展、不可耐受的不良事件或自愿退出。
  • 共同主要终点为安全性和生存≥12个月的志愿者比例,样本量为50例可评估志愿者。

主要发现

  • 50例可评估志愿者中,12个月OS为38%(n=19)。
  • 中位OS为6.1个月(95%CI:4.3-12.1),中位PFS为2.8个月(95%CI:2.6-3.0)。
  • 最常见治疗相关不良事件为疲乏、寒战、发热、恶心和贫血,大多数为1级或2级,可自行缓解或经适当治疗缓解。

关键数值与推荐

  • 根据历史GOG队列估算的合并(第一+第二阶段)12个月OS为35%,作为宣布ADXS-HPV在铂类预处理人群中具有足够活性的基准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and bevacizumab, median overall survival (OS) is only 17.0 months, with median post-progression survival of approximately seven months. We studied the therapeutic vaccine, Axalimogene filolisbac (ADXS-HPV), in women who had progressed following at least one prior line of therapy (Gynecologic Oncology Group protocol 265/NCT01266460). METHODS: Volunteers ≥18 years with advanced cervical cancer and GOG performance status score of 0 or 1 were eligible for participation in this 2-stage, phase II trial. In stage 1, women received up to three doses of ADXS-HPV (1 × 109 colony-forming units in 250 mL IV over 15 min every 28 days) and were monitored for tumor progression. In stage 2, women were treated until progression, intolerable adverse events (AEs), or voluntary withdrawal of consent. Co-primary endpoints were safety and proportion of volunteers surviving ≥12 months. An estimated, combined (stages 1 + 2) 12-month OS of 35% was calculated from historical GOG cohorts to declare ADXS-HPV sufficiently active in this platinum-pre-treated population. Secondary endpoints were OS and progression-free survival (PFS). RESULTS: Among 50 evaluable volunteers, the 12-month OS was 38% (n = 19). Median OS was 6.1 months (95% CI: 4.3-12.1) and median PFS was 2.8 months (95% CI: 2.6-3.0). The most common treatment-related AEs were fatigue, chills, fever, nausea, and anemia. The majority of AEs were grade 1 or 2 and resolved spontaneously or with appropriate treatment. CONCLUSION: At the dose and schedule studied, ADXS-HPV immunotherapy was tolerable and met the protocol-specified benchmark for activity required to warrant further investigation in volunteers with cervical carcinoma.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Huh WK, Brady WE, Fracasso PM, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020. PMID: 32641240. doi:10.1016/j.ygyno.2020.06.493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。